Mechanism of Action
NOP Receptor Signaling
N/OFQ activates the NOP receptor (OPRL1), a Gi/Go-coupled GPCR structurally related to opioid receptors but pharmacologically distinct. NOP activation inhibits adenylyl cyclase, activates GIRK channels, and inhibits voltage-gated calcium channels, identical downstream effects to classical opioid receptors, but via a receptor that is not blocked by naloxone. This naloxone insensitivity distinguishes N/OFQ from classical opioids and explains early observations of "anti-opioid" activity at supraspinal sites.
Biphasic Pain Modulation
N/OFQ's most distinctive pharmacological feature is its site-dependent bidirectional pain modulation. Supraspinal (ICV) N/OFQ produces hyperalgesia by inhibiting descending pain-inhibitory circuits. Spinal (intrathecal) N/OFQ produces analgesia by inhibiting dorsal horn pain transmission. This spatial separation of opposing effects reflects the distribution of N/OFQ-mediated pain circuit inhibition and facilitation in different anatomical compartments.
Research Summary
Pain and Analgesia
AnimalSpinal N/OFQ consistently produces analgesia in rodent models. NOP agonists with CNS penetrance tend to produce mixed analgesia/anti-analgesia depending on dose and route. Bifunctional NOP/MOR agonists like cebranopadol have entered Phase III trials for chronic pain, showing efficacy with potentially reduced abuse liability compared to pure MOR agonists.
Anxiety, PTSD, and Stress
AnimalNOP activation in the amygdala and bed nucleus of the stria terminalis produces anxiolytic effects in rodent models. N/OFQ blunts fear conditioning acquisition and facilitates fear extinction, supporting NOP agonism as a PTSD treatment approach. NOP receptor knockout mice show heightened anxiety and stress responses, confirming an endogenous anxiolytic role.
Drug Addiction
AnimalN/OFQ reduces dopamine release in the nucleus accumbens and blunts the rewarding effects of cocaine, morphine, and alcohol in animal models. NOP agonists reduce drug self-administration and relapse-like behavior. These anti-reward properties position NOP agonism as a novel approach to addiction treatment without directly blocking opioid receptors.
Calculate your Nociceptin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Spinal analgesia research | 1-100 nmol | Single intrathecal injection | Intrathecal (animal) |
| Anxiety / PTSD research | 1-10 nmol | Single ICV injection | ICV (animal) |
N/OFQ research uses central delivery in animal models. Clinical development focuses on small-molecule NOP modulators and bifunctional NOP/MOR peptides with improved pharmacokinetics.
Interactions
Safety Profile
Native N/OFQ is studied only in animal models with central delivery. Small-molecule NOP agonists entering clinical trials have generally shown favorable safety profiles compared to MOR agonists, with reduced respiratory depression and abuse potential. Cebranopadol (NOP/MOR dual agonist) in Phase III cancer pain trials showed analgesic efficacy with manageable side effects. NOP receptor systems represent a genuinely novel opioid-related target with distinct safety characteristics.
References
- [1]Meunier JC, et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature. 1995;377(6549):532-535.
- [2]Reinscheid RK, et al. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science. 1995;270(5237):792-794.
- [3]Toll L, et al. Nociceptin/orphanin FQ receptor structure, signaling, ligands, functions, and interactions with opioid systems. Pharmacol Rev. 2016.